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Abstract: Aspirin is widely used internationally for a variety of indications, with the most 
prominent one being that of cardiovascular disease. However, aspirin has also been 
proposed as a treatment option in a diverse range of conditions such as diabetes mellitus, 
cancer prevention, and obstetrics. In our overview, we critically appraise the current 
evidence from recent systematic reviews and meta-analyses covering the benefits of aspirin 
across these conditions. We also look at evidence that some patients may not derive benefit 
due to the concept of aspirin resistance. Aspirin is also associated with the potential for 
significant harm, principally from haemorrhagic adverse events. We critically appraise the 
threat of haemorrhagic complications, and weigh up these risks against that of any 
potential benefit. 
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1. Introduction 
The use of salicylic acid in medicine stretches back to antiquity. Early medicines containing 
salicylic acid were derived from willow bark and other salicylate-rich plants. These formulations were 
recognized for their antipyretic, analgesic and anti-inflammatory properties, but were also found to 
have gastrointestinal side effects. The modern form, aspirin or acetylsalicylic acid, is the acetylated 
version of the natural product and was developed with the aim of improving the tolerability of the 
drug. More recently, research into the mechanism of action of aspirin led to the discovery that it 
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inhibited the production of prostaglandins. This has resulted in a multitude of new applications for 
aspirin encompassing conditions such as cardiovascular disease, pre-eclampsia, and cancer prevention. 
The increasing numbers of people being exposed to aspirin has also led to the awareness of the 
significant potential harm arising from the adverse haemorrhagic effects of aspirin (e.g. 
gastrointestinal  and intracranial bleeds). Hence there is need to critically consider the evidence behind 
the therapeutic indications for aspirin, and decide whether the anticipated benefit outweighs the 
potential for harm. 
In patients with high risk of vascular disease, antiplatelet therapy has been shown to reduce 
vascular events by about a quarter [1,2]. The benefits of aspirin treatment in secondary prevention 
seem to outweigh the risks, but this is much less clear for primary prevention in healthy individuals 
where the risk of thrombotic cardiac events is somewhat lower [3]. A number of current guidelines 
recommend the use of aspirin in primary prevention, but do not fully consider the risk of bleeding [4–
6]. Aspirin is also widely used in certain subgroups of patients, e.g. patients with diabetes mellitus, and 
those with peripheral vascular disease, where the precise benefits have not been fully clarified. 
Moreover, there has been recent concern that some patients with cardiovascular disease are aspirin 
resistant and do not benefit from normally recommended dose of aspirin therapy and it is unclear how 
to identify such patients [7–13]. It is not understood why patients become aspirin resistant and it may 
related to inadequate dosages, poor compliance, reduced ability to absorb aspirin or genetic 
predisposition [14–19]. The validity of platelet function testing, and its correlation with cardiovascular 
event, remain a hotly debated topic. 
Aspirin may also have a role in obstetrics, particularly in conditions such as pre-eclampsia where 
vascular dysfunction in the placental beds is a potential aetiological factor. A systematic review from 
some years back suggests that aspirin has beneficial effects on important outcomes, with reductions in 
the relative risks of pre-eclampsia, preterm birth and baby death [20]. This remains a controversial area 
though, as early trials have shown conflicting results compared to more recent larger studies [21–26].  
Inhibition of cyclooxygenase may have a useful role in suppression of neoplasia, as demonstrated 
by epidemiological studies and clinical trials that have reported reduced risk of colorectal cancer with 
non-steroidal anti-inflammatory agents [27,28]. There appears to be a potential association between 
aspirin use and a reduction in the risk of colorectal cancer [28–30], and colorectal adenomas  
[27, 31–33]. The benefits of aspirin may also extend to other tumours such as breast cancer [34,35], 
and the evidence in these areas certainly merits further detailed scrutiny. Many clinical studies have 
evaluated the association between non-steroidal anti-inflammatory use and breast cancer and these 
studies have reported inconsistent results [36–45]. Two meta-analyses have pooled the data and both 
have shown similar a risk reduction for use of NSAIDS and aspirin compared to control. These 
reviews have not considered both the effect of a dose-response relationship that considers both 
frequency and duration of use.  
While the risks of gastrointestinal and cerebral haemorrhage with aspirin have already been studied 
in detail [46,47], the problems with aspirin may manifest elsewhere. The large number of patients on 
aspirin creates a conundrum for clinicians who are performing surgery or interventional vascular 
procedures on such patients, given concerns about increased risk of post-procedural bleeding from 
wound sites. Should aspirin be stopped prior to interventional procedures, bearing in mind the 
possibility of a thrombotic events? [48]. Some studies suggest that continued aspirin therapy during the 
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operation is associated with increased risk of blood transfusion during the surgery, while other studies 
have suggested the contrary, including survival benefit associated with continued use of  
aspirin [49–55]. 
The aim of this review is to update and critically appraise the evidence from recent meta-analyses 
(published within the past three years) covering the common and potential applications of aspirin and 
evaluating the benefits and harms of treatment.  
2. Experimental Methods 
Systematic reviews and meta-analyses that included adult patients who had aspirin therapy as a 
main focus were included. There was no restriction on the indication for aspirin therapy but the meta-
analysis must have reported either efficacy outcomes and/or adverse events outcomes. Studies were 
excluded if there were more recent meta-analyses reviewing the same topic. 
Recent reviews were identified by searching Medline from January 2007 until March 2010. The 
following terms and keywords were used [(aspirin) AND systematic[sb]]. The search was limited to 
meta-analyses published in English and human studies. 
The studies retrieved were checked independently by two reviewers (CSK and YKL) and relevant 
reviews were selected according to the stated inclusion and exclusion criteria. Disagreements were 
resolved by consensus. 
Data was extracted by CSK and checked by YKL. The characteristics of the participants included in 
each meta-analysis were extracted, including the total number of patients, mean age, percentage of 
females, the types of studies included, the main results and the validity of the primary studies based on 
the reviewer’s assessment. 
Where available, number needed to treat for benefit (NNTB) and harm (NNTH) were extracted 
directly from the meta-analyses of controlled trials. If not, we extracted the event rates (%) for the 
pooled control and aspirin arms in order to illustrate the absolute risk reduction/increases with aspirin. 
The NNTB and NNTH with 95% confidence intervals (95% CI) for selected key outcomes was then 
calculated by applying the relative risk to the control event rate using the Visual Rx website. 
(http://www.nntonline.net/visualrx/)  
3. Results and Discussion 
We identified 21 potentially relevant meta-analyses articles eligible for our overview. Of these, nine 
were excluded because there were more recent reviews with additional studies. Of the 12 relevant 
analyses, the key ones with quantitative data on absolute and relative risk estimates are shown in Table 
1. Study selection is shown in Figure 1. The characteristics of the trials included in the meta-analyses 
of this review are shown in Table 1, and the NNT for key outcomes are summarized in Table 2. 
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Table 1. Characteristics of key meta-analyses in current review. 
Study 
Trials 
and 
design 
Participants Outcomes Findings Quality 
Alghamdi 
2007 [62] 
10 
studies; 
5 trials, 
5 cohort 
studies 
1,748 
participants; 
913 aspirin 
group, 835 
control group 
Risk of 
bleeding in 
coronary 
artery bypass 
graft patients 
Aspirin use was 
associated with 
increase in blood loss, 
red cell and fresh 
frozen plasma 
transfusion, but not 
platelets or 
reexploration. 
Results were 
limited 
because of 
heterogeneity 
and poor 
methodologica
l quality 
Askie 2007 
[58] 
31 trials 32,217 women 
and 32,819 
babies 
Risk of pre-
eclampsia and 
pregnancy 
outcomes 
Aspirin associated 
with reduced risk of 
pre-eclampsia, 
preterm delivery <34 
weeks but no effect on 
maternal or fetal 
outcomes. 
Trial quality 
was not 
discussed 
ATC 2009 [3] 22 trials, 
6 
primary 
preventi
on, 16 
secondar
y 
preventi
on 
95,000 
participants in 
primary 
prevention, 
17,000 
participants in 
secondary 
prevention 
trials 
Risk of 
cardiovascula
r events, 
stroke, 
coronary 
events and 
death 
Primary prevention 
with aspirin therapy 
results showed 
significant reduction 
in serious vascular 
events, non-fatal MI 
but not stroke or 
vascular mortality. 
Secondary prevention 
with aspirin 
significantly reduced 
serious vascular 
events, stroke and 
coronary events. 
Significant increase in 
major extracranial 
bleeds. 
Trial quality 
was not 
discussed  
Berger 2009 
[57] 
18 trials 5,269 
participants; 
2,823 aspirin 
group, 2,446 
control group 
Risk of 
cardiovascula
r events, 
stroke, 
coronary 
events, death 
and bleeding 
Aspirin therapy 
significantly reduced 
incidence of non-fatal 
stroke but not all-
cause mortality or MI. 
Quality was 
assessed in 12 
trials, high 
quality (Jadad 
4–5) in 6 trials 
and low 
quality (Jadad 
1–3) in 6 trials 
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Table 1. Cont. 
Bujold 2009 
[59] 
9 trials 1,317 women Risk of pre-
eclampsia and 
pregnancy 
outcomes 
Aspirin therapy before 
<16 weeks was 
associated with 
reduced pre-
eclampsia, severe 
preeclampsia and 
gestational 
hypertension. 
Mixed quality of 
trials as 5/9 
were double-
blind, 6/9 used 
ITT and most 
had <6% loss to 
follow up 
Cole 2009 
[60] 
4 trials 2,967 
participants; 
1,289 control, 
1,678 aspirin 
Risk of 
adenomas and 
adverse 
events 
Aspirin therapy 
significantly reduced 
both adenomas and 
advanced lesions 
compared to placebo. 
One trial was 
small and had 
many drop outs 
and there was no 
formal quality 
assessment  
De Berardis 
2009 [56] 
6 trials 10117 
participants 
Risk of 
cardiovascula
r events, death 
and adverse 
events 
Aspirin therapy in 
diabetes patient was 
associated with no 
significant reduction 
in cardiovascular 
events, cardiovascular 
mortality or overall 
mortality. 
Quality was 
suboptimal in 
some studies, 
3/6 had adequate 
allocation 
concealment, all 
studies were 
adequately 
blinded and 5/6 
used ITT 
principles 
Kraspoulos 
2008 [13] 
20 
studies; 1 
trial, 19 
cohort 
studies 
2,930 
participants 
Risk of 
cardiovascula
r events, 
stroke, 
coronary 
events, death 
and vascular 
interventions 
Among aspirin 
resistant patient there 
is significantly 
increased risk of 
cardiovascular event, 
death and acute 
coronary syndrome. 
Quality of trials 
was high in 
17/20 trials and 
remaining trials 
lacked 
information on 
quality 
Lewis 2007 
[63] 
6 cohorts 
studies, 4 
included 
aspirin 
1,373 
participants 
Risk of 
complications 
in surgery 
Aspirin therapy was 
associated with 
statistically significant 
increase in 
complications. 
All studies had 
limitations and 
potential biases 
due to 
observational 
designs 
Mangiapane 
2008 [61] 
10 cohort 
studies 
236,655 
participants 
Risk of breast 
cancer 
Aspirin therapy was 
associated with 
statistically significant 
reduction in breast 
cancer. 
Quality was not 
discussed 
MI = myocardial infarction; ITT = intention to treat analysis 
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Figure 1. Flow diagram of selection of meta-analysis included in review. 
 
Table 2. Number Needed to Treat for Key Outcomes in Meta-Analyses of Aspirin versus Control. 
Application of 
aspirin 
Risk of event 
(95% 
confidence 
interval) 
Treated event 
rate Control event rate 
Number needed 
to treat 
Primary and secondary prevention of cardiovascular disease 
Primary 
prevention of 
non-fatal MI 
RR 0.77 (0.67–
0.89) 
0.18% per year 0.23% per year 1891 (NNTB 
1318– 3953) per 
year 
Secondary 
prevention of 
non-fatal MI 
RR 0.69 (0.60–
0.80) 
6.7% per year 8.2% per year 40 (NNTB 31– 
61) per year 
Primary 
prevention of 
stroke 
RR 0.95 (0.85–
1.06) 
0.20% per year 0.21% per year No significant 
benefit 
Secondary 
prevention of 
stroke 
RR 0.81 (0.71–
0.92) 
2.08% per year 2.54% per year 208 (NNTB 136– 
493) per year 
Major GI and 
extracranial 
bleeds in primary 
prevention 
RR 1.54 (1.30–
1.82) 
0.10% per year 0.08% per year 2315 (NNTH 
1525–4167) per 
year 
Major GI and 
extracranial 
bleeds in 
secondary 
prevention 
RR 2.69 (1.25– 
5.76) 
0.17% per year 0.07% per year 846 (NNTH 
301–5715) per 
year 
 
 
 
Meta-analysis included in the review 
of aspirin (n = 12)  
Potentially relevant reviews 
identified, and titles and abstracts  
screened (n = 21)
9 reviews were excluded because there were 
more updated reviews.  
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Table 2. Cont. 
Patients with peripheral vascular disease 
Major 
cardiovacular 
events 
RR 0.88 (0.76– 
1.04) 
8.9% (from 10 
days to 6.7 
years) 
11.0% (from 10 
days to 6.7 years) 
No significant 
benefit 
Nonfatal stroke RR 0.66 (0.47–
0.94) 
2.1% (from 10 
days to 6.7 
years) 
3.1% (from 10 days 
to 6.7 years) 
95 (NNTB 61–
538) (from 10 
days to 6.7 
years) 
Patients with diabetes 
Major 
cardiovascular 
events 
RR 0.90 (0.81– 
1.00) 
12.5% (from 3– 
10 years) 
13.7% (from 3–10 
years) 
No significant 
benefit 
Patients with pre-eclampsia 
Risk of pre-
eclampsia 
RR 0.90 (0.84–
0.97) 
7.9% during 
course of 
pregnancy 
8.7% during course 
of pregnancy 
 
115 (NNTB 72–
384) during 
course of 
pregnancy 
Patients with colorectal adenoma 
Prevention of any 
adenoma 
RR 0.83 (0.72– 
0.96) 
32.9% over 33 
months 
36.7% over 33 
months 
17 (NNTB 10–
69) over 33 
months 
Prevention of 
advanced 
adenomas 
RR 0.72 (0.57– 
0.90) 
8.7% over 33 
months 
11.9% over 33 
months 
31 (NNTB 20–
85) over 33 
months 
3.1. Aspirin in cardiovascular disease 
Four meta-analyses reviewed the use of aspirin therapy for cardiovascular prevention in different 
patient populations. One paper considered the benefits of aspirin in both primary and secondary 
prevention of vascular diseases [3] while the other meta-analyses reviewed the role of aspirin in other 
patient groups such as patients with diabetes, [56] peripheral vascular disease [57] and  
aspirin resistance [13]. 
The largest meta-analysis evaluated a variety of cardiovascular and haemorrhagic events in six 
primary prevention trials and 16 secondary prevention trials [3]. All the studies included in the meta-
analysis were randomized controlled trials. For primary prevention, aspirin therapy was associated 
with a significant risk reduction in non-fatal MI (RR 0.77 95% CI 0.67–0.89), absolute risk 0.18% 
with aspirin versus 0.23% with control). However, there was no statistically significant risk reduction 
for important outcomes such as death from coronary heart disease (RR 0.95 95% CI 0.78–1.15, 
absolute risk 0.11% with aspirin versus 0.12% with control) or stroke (RR 1.21, 95% CI 0.84–1.74, 
absolute risk 0.20% with aspirin versus 0.21% with control). On the other hand in secondary 
prevention there is a significant reduction in most cardiovascular outcomes encompassing non-fatal MI 
(RR 0.69 95% CI 0.60-0.80), death from coronary heart disease (RR 0.87 95% CI 0.78–0.98) and 
stroke (RR 0.81 95% CI 0.71–0.92). The absolute risk for events in secondary prevention trial of 
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aspirin compared to control was 6.7% versus 8.2% for serious vascular events, 2.08% versus 2.54% 
for total stroke and 4.3% versus 5.3% for coronary events. This meta-analysis also showed that aspirin 
therapy significantly increased major extracranial bleeds (RR 2.69 95% CI 1.25–5.76) and was 
associated with a trend towards more haemorrhagic strokes (RR 1.67 95% CI 0.97–2.90). In view of 
the potentially serious harm, the authors conclude that there is still uncertainty regarding the net value 
of aspirin therapy in primary prevention, and aspirin use in such patients may not be warranted due to 
their low absolute risk reduction with high NNTs. 
Another meta-analysis reviewed the subgroup of patients with peripheral artery disease [57] and 
included 18 prospective randomized trials with 5,269 participants. The pooled results of any aspirin 
therapy compared to control group showed no statistical difference for major cardiac events (RR 0.88, 
95% CI 0.76–1.04), non-fatal MI (RR 1.04 95% CI 0.78–1.39, absolute risk 3.3% with aspirin versus 
3.6% with control), or cardiovascular death (RR 0.94 95% CI 0.74–1.19, absolute risk 4.6% with 
aspirin versus 5.2% control group). The only apparent benefit seemed to be a significant reduction in 
non-fatal stroke with aspirin therapy (alone or combined with other antiplatelet agents) compared to 
controls (RR 0.66 95% CI 0.47–0.94, absolute risk 1.8% with aspirin versus 3.1% with control). 
Treatment with aspirin monotherapy showed similar results with statistical significance for non-fatal 
stroke (RR 0.64, 95% CI 0.42–0.99, absolute risk 2.1% with aspirin versus 3.4% with control) but no 
significant benefit for myocardial infarction (RR 0.88 95% CI 0.36–2.14, absolute risk 3.9% with 
aspirin versus 4.5% with control), cardiovascular death (RR 1.15 95% 0.78–1.68, absolute risk 3.6% 
with aspirin versus 3.3% with control), and overall mortality (RR 0.96 95% CI 0.75–1.22, absolute risk 
7.5% with aspirin versus 7.9% with control). The authors conclude that aspirin does not have 
significant benefit on cardiovascular events overall compared to placebo in patients with peripheral 
vascular disease, other than for the outcome of nonfatal stroke. This challenges the common practice 
of using aspirin in subgroups of patients with peripheral arterial disease who do not have any other 
significant cardiovascular pathology. 
Cardiovascular morbidity and mortality are major concerns in patients with diabetes mellitus and a 
variety of treatment options have been proposed. The impact of aspirin in patients with diabetes was 
reviewed in a meta-analysis that included six randomized controlled trials and 10,117 participants [56]. 
The pooled analysis reported no significant difference between aspirin and control group for important 
outcomes such as myocardial infarction (RR 0.86 95% CI 0.61–1.21, absolute risk 12.5% with aspirin 
versus 13.7% with control), stroke (RR 0.83 95% CI 0.60–1.14, absolute risk 3.8% with aspirin versus 
4.2% with control), and all cause mortality (RR 0.93 95% CI 0.82–1.05, absolute risk 11.5% with 
aspirin versus 12.3% with control). There were trends towards increased adverse effects such as any 
bleeding (RR 2.50 95% CI 0.76–8.21), gastrointestinal bleeding (RR 2.11 95% CI 0.64–6.95) and 
gastrointestinal symptoms (RR 5.09 95% CI 0.08–314.39). However this review was limited because 
of heterogeneity in the analysis which could not be fully explored due to limited data. The authors 
concluded that aspirin cannot be routinely recommended for primary prevention of cardiovascular 
events in patients with diabetes mellitus, and further research need to be conducted. 
The fourth meta-analysis reviewed aspirin resistance and risk of cardiovascular mortality in 20 
studies of 2,930 participants [13]. Only one study in the meta-analysis a prospective randomized trial 
and the remaining 19 were cohort studies. This meta-analysis found that there was significant increase 
in risk of death (OR 5.99 95% CI 2.28–15.72), acute coronary syndrome (OR 4.06 95% CI 2.96–5.56), 
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and cerebrovascular events (OR 3.85 95% CI 3.08–4.80) among patients with laboratory defined 
“aspirin resistance”. This study had the advantage that 17 of the 20 trials had low risk of bias. 
However, amongst the limitations were the inability to evaluate the patients’ comorbidities, 
uncertainty as to which platelet function test is most reliable, and difficulty in ruling out treatment 
non-compliance as a cause of “aspirin resistance”. This study concludes that aspirin resistance 
adversely affects clinical outcomes but doctors should consider the evidence with caution as the 
overall benefit of aspirin is well proven in large trials. There is also little evidence on the best 
management strategies for patients who are found to be aspirin resistant on laboratory testing, nor do 
we know if these patients have similar or lower risks of haemorrhagic adverse effects. 
3.2. Aspirin in obstetrics 
Two meta-analyses reviewed the use of aspirin therapy in the prevention of pre-eclampsia and other 
outcomes of pregnancy [58,59]. One review reported the results from an individual patient data meta-
analysis of 31 randomized control trials that included 32,217 women and 32,819 babies [58]. 
Antiplatelet agents were associated with a significant reduction of obstetric outcomes such as pre-
eclampsia (RR 0.90 95% CI 0.84–0.97, absolute risk of events 7.9% with aspirin versus 8.7% with 
control) and preterm birth before 34 weeks gestation (RR 0.90 95% CI 0.83–0.98, absolute risk 6.5% 
with aspirin versus 7.2% with control) compared to placebo. However, antiplatelet use did not seem to 
significantly affect the risk of certain maternal outcomes such as ante-partum haemorrhage (RR 1.02, 
95% CI 0.90–1.15, absolute risk 3.8% with aspirin versus 3.7% with control), Caesarian section (RR 
1.03, 95% CI 0.99–1.08, absolute risk 22.9% with aspirin versus 22% with control) and post-partum 
haemorrhage (RR 1.06 95% CI 1.00–1.13, absolute risk 15.3% with aspirin versus 14.5% with 
control). For fetal outcomes, antiplatelet use was associated with significant reductions in preterm 
birth <37 weeks (RR 0.93 95% CI 0.89–0.98, absolute risk 16.8% with aspirin versus 18.0% with 
control) and need for infant ventilation (RR 0.79 95% CI 0.67–0.95, absolute risk 5.5% with aspirin 
versus 6.8% with control) but this was not significant for preterm birth <28 weeks (RR 0.87 95% CI 
0.75–1.02, absolute risk 1.9% with aspirin versus 2.2% with control). In this meta-analysis, the authors 
did not find any significant benefit in reducing fetal death (RR 0.91 95% CI 0.81–1.03) or preventing 
growth retardation (small for gestational age) (RR 0.90 95% CI 0.85–0.96) The authors concluded that 
antiplatelet agents show moderate (but consistent) reductions in risk of pre-eclampsia, and preterm 
birth before 34 weeks’ gestation. However, there were many other outcomes where the benefits of 
antiplatelet therapy were unproven. 
A more recent review specifically evaluated the use of aspirin in preventing pre-eclampsia and 
intra-uterine growth restriction in women who are at risk of pre-eclampsia [59]. This review evaluated 
the results of nine randomized controlled trials with 1,317 women and looked for differences in 
outcomes according to the time of treatment initiation. The reviewers reported that aspirin use before 
16 weeks gestation was associated with a significant reduction in pre-eclampsia (RR 0.48 95% CI 
0.33–0.68, absolute risk 23.3% with aspirin versus 47.2% with control) while treatment afterwards at 
17-19 weeks (RR 0.55 95% CI 0.17–1.76, absolute risk 7.7% with aspirin versus 14.0% with control) 
and 20 weeks and beyond (RR 0.82 95% CI 0.62–1.09, absolute risk 14.3% with aspirin versus 17.4% 
with control) was not significantly better than control. Compared to control, aspirin therapy initiated 
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before 16 weeks led to lower rates of severe preeclampsia [RR 0.38 95% CI 0.15–0.98, NNT 21  
(13–50)], gestational hypertension [RR 0.61 95% CI 0.40–0.93, NNT 10 (6–50)] and intra-uterine 
growth restriction (RR 0.51 95% CI 0.28–0.92) but no difference in preterm birth (RR 0.93 95% CI 
0.46–1.90). There was no significant difference for overall for aspirin therapy (commenced at any 
time) compared to control group for birth weight and gestational age at birth. This study concluded 
that the benefits of aspirin therapy were only observed in the subgroup of patients that were treated 
prior to 16 weeks gestation. 
3.3. Aspirin in neoplastic conditions 
The most recent review of aspirin therapy in preventing the development of colorectal adenomas 
was included in this review [60]. The meta-analysis included four randomized double-blind controlled 
trials that investigated the secondary prevention of colorectal adenoma in 1,289 participants in the 
placebo group and 1,678 participants in the aspirin (81–325 mg daily dose) group. Recurrence of 
adenoma was checked with colonoscopy, and the trials had a median follow-up of 33 months. This 
review reported that any dose of aspirin compared to placebo was associated with a reduced risk of 
adenoma (RR 0.83 95% CI 0.72–0.96, absolute risk 32.9% with aspirin versus 36.7% with control) and 
advanced lesions (RR 0.72 95% CI 0.57–0.90, absolute risk 8.7% with aspirin versus 11.9% with 
control). In terms of adverse events, the rate of death, myocardial infarction, major bleeding and new 
cancer diagnosis was not significantly different in both aspirin and placebo group. However, all 
reported cases of stroke occurred in the aspirin-treated group. This review concluded that trial data 
supports the use of aspirin in reducing the risk of recurrent colorectal adenomas. 
One meta-analysis reviewed the use of aspirin therapy in chemoprotection of breast cancer [61]. 
This recent meta-analysis included 10 observational studies comprising of four cohort studies and six 
case control studies. There was a significant difference in reduction of breast cancer with aspirin 
therapy compared to control (RR 0.75 95% CI 0.64–0.88) in a random-effects meta-analysis. 
Stratifying for study design, the risk reduction with aspirin was greater in the case control studies (RR 
0.70 95% CI 0.56–0.87) compare to cohort studies (RR 0.82 95% CI 0.73–0.92). Using two different 
models to study dose-response relationships, Berlin (ppw1 and dur1) and Il’yasova (ppw2 and dur2), 
both methods showed significant protective effect with high frequency of aspirin use (ppw1 = 0.002 
and ppw2 = 0.001), but only the Il’yasova method was significant (dur1 = 0.06, dur2 = 0.04) for 
duration. The results of this review concluded that current evidence suggests the use of aspirin may 
reduce the risk of breast cancer and a dose-response relationship exists. However, the validity of the 
data is limited because of heterogeneity, difference in determining aspirin exposure, and risk of bias 
from the observational designs. 
3.4. Adverse effects of aspirin in patients having surgical procedures 
Two meta-analyses reviewed the haemorrhagic adverse effects of aspirin therapy in patients 
undergoing invasive procedures. One evaluated the use of aspirin in surgical revascularization of 
coronary artery disease [62] and the other reviewed the use of aspirin in cutaneous surgery [63]. 
One meta-analysis reviewed the risk of bleeding with pre-operative aspirin therapy [62]. This meta-
analysis reviewed ten studies with 1,748 patients, with 913 patients on aspirin therapy within seven 
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days of surgery, and 835 patients in the control (non-aspirin exposed) group. Five trials out of the ten 
were randomized controlled trials while the remaining five were cohort studies. Pooling of all studies 
showed increased chest tube loss in the aspirin group that was significantly different from the control 
group (WMD = 210 mL 95% CI 87–333 mL, p < 0.01). Patients in the control group has a 
significantly reduced requirement for blood products such as packed red blood cell transfusion  
(WMD = 0.65 units/patients 95% CI 0.19–1.10 units/patient, p = 0.01) and fresh frozen plasma  
(WMD = 0.61 units/patient 95% CI 0.07–1.16 units/patient, p = 0.03), with a trend towards for platelet 
infusion (WMD = 0.6 units/patient 95% CI 0.04–1.24 units/patient, p = 0.06). Reexploration for 
bleeding was increased in the group treated with aspirin which was significant (RR 2.32 95% CI 1.31–
4.08, p < 0.01). This review concluded that patients who receive aspirin within seven days of surgery 
were at higher risk of blood loss, but the validity of the data was limited because many studies were of 
low methodological quality. 
Aspirin use in dermatological surgery is associated with increased risk of post operative bleeding 
but consensus about anticoagulation use is less clear. Studies have reported mixed results regarding the 
risk of postoperative bleeding and complications [64–67]. A meta-analysis of four prospective studies 
and two retrospective studies with a total of 1,373 patients reported that aspirin or NSAIDs was 
associated with increased risk of moderate to severe complications compared to controls (OR 2.0 95% 
CI, 0.97–4.13, p = 0.06). This study concluded that there is a low but significant risk of complications 
associated with use of anticoagulants but this risk is greater with warfarin than aspirin. 
3.5. Aspirin and Gastrointestinal Harm 
The effects of aspirin on gastrointestinal haemorrhage were systematically reviewed by Derry and 
Loke almost 10 years ago [47]. This meta-analysis found a NNT for harm of 106 over 28 months, with 
a fairly flat dose-response curve over the range 50 mg–325 mg, and little evidence for the purported 
benefits of modified release formulations. A more recent ‘best evidence’ review focusing on enteric-
coated aspirin concluded that the available data showed no significant risk reduction for 
gastrointestinal bleeding or ulceration. [68]. Serious complications from upper gastrointestinal 
bleeding and perforation continues to be a major problem, with a recent systematic review showing 
that since 1997, mortality rates from gastrointestinal complications have continued to rise in aspirin 
and non-steroidal anti-inflammatory users [69]. 
4. Conclusions 
This overview of recently published meta-analyses suggests that aspirin therapy has significant 
benefits in a variety of clinical settings, but there are still uncertainties that will require more research. 
Current evidence suggests that aspirin is beneficial for secondary prevention for cardiovascular 
disease, primary prevention of pre-eclampsia, and secondary prevention of colorectal adenomas. 
However, use of aspirin in primary prevention of cardiovascular disease, or in patients with diabetes 
mellitus, or in those with peripheral vascular disease is not supported by the current evidence. It is also 
clear that aspirin has considerable potential for harm in patients undergoing surgical procedures. The 
benefits of aspirin use must be weighed clinically against the risk of adverse events such as 
gastrointestinal and intracranial bleeding.  
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